A new study published in Clinical Infectious Diseases, reports estimates of healthcare costs associated with infections due to multidrug-resistant bacteria in the United States. Antimicrobial-resistant infections lead to substantial healthcare costs extrapolated to annual national costs exceeding $4.6 billion.
This is one of the largest studies to estimate the attributable cost associated with 6 high-priority antibiotic-resistant pathogens:
- Methicillin-resistant Staphylococcus aureus (MRSA)
- Extended-spectrum cephalosporin resistance in Enterobacteriaceae suggestive of extended-spectrum β-lactamase (ESBL) production
- Vancomycin-resistant Enterococcus (VRE)
- Carbapenem-resistant Acinetobacter species (CRAsp)
- Carbapenem-resistant Enterobacteriaceae (CRE)
- Multidrug-resistant (MDR) Pseudomonas aeruginosa.